Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Aldeyra Therapeutics (Nasdaq: ALDX), a biotechnology company focused on developing therapies for immune-mediated and metabolic diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will engage in a fireside chat with Matthew Caufield, Director of Equity Research at H.C. Wainwright & Co.

The conversation is scheduled for September 11, 2024, at 11:30 a.m. ET. Investors and interested parties can access the live webcast through the Investors & Media section of Aldeyra's website. The webcast will remain archived for 90 days following the event, providing an opportunity for those unable to attend live to catch up on the discussion.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 26^th Annual Global Investment Conference.

Dr. Brady’s conversation with Matthew Caufield, Director, Equity Research at H.C. Wainwright & Co., is scheduled to begin at 11:30 a.m. ET Wednesday, September 11, 2024. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following the fireside chat, the webcast will be archived for 90 days.

About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240905757334/en/

Investors & Media:

David Burke

(917) 618-2651

investorrelations@aldeyra.com

Source: Aldeyra Therapeutics, Inc.

FAQ

When is Aldeyra Therapeutics (ALDX) participating in the H.C. Wainwright Global Investment Conference?

Aldeyra Therapeutics (ALDX) is participating in the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, with a fireside chat scheduled for 11:30 a.m. ET.

Who will represent Aldeyra Therapeutics (ALDX) at the H.C. Wainwright conference?

Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra Therapeutics, will represent the company at the H.C. Wainwright conference.

How can investors access Aldeyra Therapeutics' (ALDX) presentation at the H.C. Wainwright conference?

Investors can access the live webcast of Aldeyra Therapeutics' (ALDX) presentation through the Investors & Media section of the company's website at https://ir.aldeyra.com.

How long will the webcast of Aldeyra Therapeutics' (ALDX) presentation be available after the conference?

The webcast of Aldeyra Therapeutics' (ALDX) presentation will be archived and available for 90 days following the conference.